The decision to take medication during pregnancy is difficult. However, chronic dehydration and malnutrition due to Hyperemesis Gravidarum (HG) carry risks that may be greater than the tiny possible risks of ondansetron or other medications. Taking Zofran (ondansetron) during pregnancy is effective for >60% of HG patients.
Ondansetron (Zofran) is a Class B serotonin antagonist. This class of medication is found to improve symptoms in > 80% of women.
Tips for taking Zofran (ondansetron) during pregnancy
- lasts about 6 hours
- take with a daily stool softener
- take on a strict schedule
- dose: 4 mg every 3-6 hours OR 8 mg every 6 hours
- maximum 32 mg throughout the day
Routes for taking Zofran (ondansetron)
- Tablet (oral)
- ODT (oral or vaginal)
- Compounded
- Subcutaneous pump
- IV
More To Know About Ondansetron
If you have pre-existing medical conditions (diabetes, heart disease, etc.), a history of medication reactions, or are a smoker, please inform your physician before taking these medications.
Often effective in patients who have multiple triggers (smell, motion, etc.), a history of hormone sensitivity, and/or moderate to severe vomiting.
If a patient has a history of HG that responded to serotonin antagonists, it should be considered as a first line drug to minimize symptom severity.
Dosing throughout pregnancy may prevent relapse or stabilize symptoms.
Avoid use with other serotonin antagonists (e.g. SSRI’s, antidepressants) to prevent serotonin syndrome.
More common side-effects: Headache, mild/moderate (reversible) liver function test abnormalities, constipation*, diarrhea
GET INVOLVED
- Participate in HG research.
- Become an advocate.
- Make a gift to the HER Foundation.
- Share your story and support other HG moms.
- Become a HER Foundation volunteer.
- Blog about HG and show support for HER.
- Share resources with local health professionals and hospitals.
©2022 HER Foundation. All rights reserved.
Note: HER Foundation does NOT receive any funds from the sales of Zofran or it’s generic equivalents.
